Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.01 USD | -2.91% | +0.25% | -30.62% |
May. 29 | Transcript : BridgeBio Pharma, Inc. - Special Call | |
May. 28 | UBS Adjusts Price Target on BridgeBio Pharma to $47 From $51, Maintains Buy Rating | MT |
Financials (USD)
Sales 2024 * | 361M | Sales 2025 * | 263M | Capitalization | 5.24B |
---|---|---|---|---|---|
Net income 2024 * | -450M | Net income 2025 * | -516M | EV / Sales 2024 * | 17.2 x |
Net Debt 2024 * | 968M | Net Debt 2025 * | 1.44B | EV / Sales 2025 * | 25.4 x |
P/E ratio 2024 * |
-10.3
x | P/E ratio 2025 * |
-9.74
x | Employees | 553 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.93% |
Latest transcript on BridgeBio Pharma, Inc.
1 day | -2.91% | ||
1 week | +0.25% | ||
1 month | +9.33% | ||
3 months | -17.98% | ||
6 months | -2.44% | ||
Current year | -30.62% |
Managers | Title | Age | Since |
---|---|---|---|
Neil Kumar
FOU | Founder | 45 | 14-12-31 |
Charles Homcy
FOU | Founder | 75 | 14-12-31 |
Founder | 73 | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Momtazee
BRD | Director/Board Member | 52 | 16-02-29 |
Founder | 73 | 14-12-31 | |
Fred Hassan
BRD | Director/Board Member | 78 | 21-08-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.35% | 2 M€ | -.--% | ||
0.12% | 7 M€ | -.--% | - | |
0.11% | 0 M€ | 0.00% | - | |
0.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 28.01 | -2.91% | 1,547,905 |
24-05-30 | 28.85 | +4.49% | 1,543,488 |
24-05-29 | 27.61 | -0.75% | 2,519,047 |
24-05-28 | 27.82 | -0.43% | 1,995,909 |
24-05-24 | 27.94 | +0.65% | 980,432 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.62% | 5.24B | |
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |
- Stock Market
- Equities
- BBIO Stock